CN103784589B - One is prevented and treats haemophiliachemophiliac compound medicine - Google Patents
One is prevented and treats haemophiliachemophiliac compound medicine Download PDFInfo
- Publication number
- CN103784589B CN103784589B CN201410049630.8A CN201410049630A CN103784589B CN 103784589 B CN103784589 B CN 103784589B CN 201410049630 A CN201410049630 A CN 201410049630A CN 103784589 B CN103784589 B CN 103784589B
- Authority
- CN
- China
- Prior art keywords
- compound medicine
- radix
- haemophiliachemophiliac
- blood
- treat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 150000001875 compounds Chemical class 0.000 title claims abstract description 47
- 241000427159 Achyranthes Species 0.000 claims abstract description 11
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 11
- 241001647745 Banksia Species 0.000 claims abstract description 11
- 241000756943 Codonopsis Species 0.000 claims abstract description 11
- 241000110637 Cuscuta chinensis Species 0.000 claims abstract description 11
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 11
- 244000286838 Eclipta prostrata Species 0.000 claims abstract description 11
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 11
- 239000009636 Huang Qi Substances 0.000 claims abstract description 11
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 11
- 241000155182 Monochasma Species 0.000 claims abstract description 11
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 11
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 11
- 241000208966 Polygala Species 0.000 claims abstract description 11
- 244000197580 Poria cocos Species 0.000 claims abstract description 11
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 11
- 241000405414 Rehmannia Species 0.000 claims abstract description 11
- 241000220317 Rosa Species 0.000 claims abstract description 11
- 235000000125 common agrimony Nutrition 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 10
- 244000157790 Buglossoides arvense Species 0.000 claims abstract description 9
- 235000004256 Buglossoides arvense Nutrition 0.000 claims abstract description 9
- 239000008187 granular material Substances 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000007884 disintegrant Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 239000012982 microporous membrane Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000002265 prevention Effects 0.000 abstract description 13
- 230000008901 benefit Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000000295 complement effect Effects 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 47
- 239000008280 blood Substances 0.000 description 47
- 208000032843 Hemorrhage Diseases 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 19
- 208000034158 bleeding Diseases 0.000 description 16
- 231100000319 bleeding Toxicity 0.000 description 16
- 230000000740 bleeding effect Effects 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 235000009508 confectionery Nutrition 0.000 description 13
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 10
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 10
- 239000003114 blood coagulation factor Substances 0.000 description 10
- 208000009292 Hemophilia A Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 208000006750 hematuria Diseases 0.000 description 7
- 208000031220 Hemophilia Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 208000001780 epistaxis Diseases 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 102100026735 Coagulation factor VIII Human genes 0.000 description 4
- 208000034507 Haematemesis Diseases 0.000 description 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 206010046788 Uterine haemorrhage Diseases 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 206010033675 panniculitis Diseases 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 210000000697 sensory organ Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000004304 subcutaneous tissue Anatomy 0.000 description 4
- 206010000077 Abdominal mass Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000027219 Deficiency disease Diseases 0.000 description 3
- 206010014080 Ecchymosis Diseases 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 210000001624 hip Anatomy 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 206010049865 Achromotrichia acquired Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000012287 Prolapse Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 244000061458 Solanum melongena Species 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000022182 gross hematuria Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- JONFYSWOLCTYFK-UHFFFAOYSA-N 2-(2,3-dichloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(Cl)=C1Cl JONFYSWOLCTYFK-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010072081 Bandaemia Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 206010039740 Screaming Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000009596 Tooth Mobility Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229950009130 clofenamic acid Drugs 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- -1 sorbierite Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of prevention and treat haemophiliachemophiliac compound medicine.This prevention and to treat haemophiliachemophiliac compound medicine formulated according to shown weight ratio scope by following components, moutan bark 27～33, glutinous rehmannia 23～35, the radix paeoniae rubrathe 13～18, the seed of Chinese dodder 12～17, savatier monochasma herb 5～10, cornu bubali 10～20, cacumen biotae 7～14, Poria cocos 10～15, eclipta 18～23, the fruit of glossy privet 9～12, the Radix Astragali 6～15, Radix Codonopsis 13～17, RADIX POLYGONI MULTIFLORI PREPARATA 3～8, Asian puccoon 11～13, Radix Angelicae Sinensis 16～20, the root of bidentate achyranthes 4～9, arillus longan 11～15, the banksia rose 9～12, polygala root 15～18, hairyvein agrimony 8～13, pseudo-ginseng 10～15.The present invention is complementary to one another coordination by reasonable compatibility, effect of effective component and each component assisting a ruler in governing a country composition, has advantages such as short treating period, instant effect, good effect, and is pure natural crude drug compatibility, will not have side effects, dependence and the resistance to the action of a drug.
Description
Technical field
The present invention relates to a kind of prevention and treat haemophiliachemophiliac compound medicine.
Background technology
Hemophilia (hemophilia) is one group of hereditary hemorrhagic disease more typically, has X connection recessiveness
The feature of heredity, different according to the clotting factor lacking, FVIII deficiency disease and FIX deficiency disease can be divided into,
Cause APTT dyspoiesis owing to FVIII or FIX procoagulant activity reduces, cruor time extending, all the life
There is abnormal bleeding tendency after minor trauma.It is embodied in Juvenile onset, goes out after spontaneous or slight wound
Blood is more than, hemotoncus is formed and arthrorrhagia.Owing to patients blood plasma lacking certain clotting factor, the blood of patient
After tracheal rupture, blood calibration ordinary person is difficult to condense, thus can the more blood of diffluence.Caused by the wound of body surface
Bleeding generally serious, internal haemorrhage then serious much.Internal haemorrhage typically occur in joint, tissue and
Inside muscle.When visceral hemorrhage or intracranial hemorrhage generation when, usually threat to life.The active water of clotting factor
Flat also different, haemophiliac can be divided into heavy type, medium-sized and light-duty accordingly.Treatment side the most frequently used at present
Method is defeated clotting factor, but this method can only maintain the short period, after a period of time the blood coagulation in blood because of
Son can reduce again, and patient needs frequent defeated clotting factor to maintain, and clotting factor is expensive, to typically
For family, financial burden is heavier.Suffer from haemophiliachemophiliac patient's daily need exactissima diligentia protection health to avoid
Collide with, also bring inconvenience to daily life.Traditional Chinese medicine is thought when a variety of causes causes train of thought to be damaged or blood
Blood from overflowing arteries and veins will be caused during the absurd row of liquid outer and form blood trouble.The reason that cause blood trouble a lot of, but with regard to blood friend
For Bing, being mainly summarized as follows: the first, inadequate natural endowment, damage of kidney-essence is fire excess from yin deficiency, and the fire of deficiency type is burnt network, compels
The absurd row of blood and cause bleeding, this is the main cause of hemophilia bleeding.2nd, damaged by excess of seven emotions, ponder over angry excessively,
So that upward invasion of liver-QI or liver depression forming fire are damaged train of thought and are caused bleeding.3rd, eating and drinking without temperance addiction pure wine savoury,
Drinking too much and the pungent savoury of overfeeding, or grow damp and hot, thermal burn train of thought, or impairing the spleen and stomach, blood loses
Have under one's command and cause bleeding.4th, the overstrain overstrain damage heart, spleen, kidney.Cause gas not take the photograph if feeling frustrated
Blood, hinders essence and then causes fire excess from yin deficiency, and then cause bleeding.
Content of the invention
The technical problem to be solved in the present invention is the drawbacks described above how overcoming prior art, provides one prevention
And treat haemophiliachemophiliac compound medicine.
For solving above-mentioned technical problem, this prevention and treat haemophiliachemophiliac compound medicine by following components according to institute
Show that weight ratio scope is formulated, moutan bark 27～33, glutinous rehmannia 23～35, the radix paeoniae rubrathe 13～18, the seed of Chinese dodder
12～17, savatier monochasma herb 5～10, cornu bubali 10～20, cacumen biotae 7～14, Poria cocos 10～15, eclipta 18～23,
The fruit of glossy privet 9～12, the Radix Astragali 6～15, Radix Codonopsis 13～17, RADIX POLYGONI MULTIFLORI PREPARATA 3～8, Asian puccoon 11～13, Radix Angelicae Sinensis 16～20,
The root of bidentate achyranthes 4～9, arillus longan 11～15, the banksia rose 9～12, polygala root 15～18, hairyvein agrimony 8～13, pseudo-ginseng 10～15.
As optimum ratio, this prevention and treat haemophiliachemophiliac compound medicine by following components according to shown weight
Part proportion is formulated, moutan bark 29～31, glutinous rehmannia 27～29, the radix paeoniae rubrathe 14～16, the seed of Chinese dodder 14～16,
Savatier monochasma herb 7～9, cornu bubali 15～17, cacumen biotae 9～11, Poria cocos 12～14, eclipta 19～21, glossy privet
Son 9～11, the Radix Astragali 11～13, Radix Codonopsis 15～17, RADIX POLYGONI MULTIFLORI PREPARATA 5～7, Asian puccoon 10～12, Radix Angelicae Sinensis 17～19,
The root of bidentate achyranthes 6～8, arillus longan 12～14, the banksia rose 10～12, polygala root 16～18, hairyvein agrimony 8～10, pseudo-ginseng 11～13.
As optimum proportioning, this prevention and treat haemophiliachemophiliac compound medicine by following components according to shown weight
Part proportion is formulated, and moutan bark the 30th, glutinous rehmannia the 28th, the radix paeoniae rubrathe the 15th, the seed of Chinese dodder the 15th, savatier monochasma herb is the 8th,
Cornu bubali the 16th, cacumen biotae the 10th, Poria cocos the 13rd, eclipta the 20th, the fruit of glossy privet the 10th, the Radix Astragali the 12nd, Radix Codonopsis is the 16th,
RADIX POLYGONI MULTIFLORI PREPARATA the 6th, Asian puccoon the 11st, Radix Angelicae Sinensis the 18th, the root of bidentate achyranthes the 7th, arillus longan the 13rd, the banksia rose the 11st, polygala root the 17th, hairyvein agrimony
9th, pseudo-ginseng 12.
As optimization, this compound medicine formulation is tablet, capsule, powder-injection or granule.
This prevention and to treat haemophiliachemophiliac compound medicine be tablet；Its preparation method is, by above-mentioned weight portion
Proportioning weighs each component, the filler of addition 35%～50%, adhesive, disintegrant, lubricant, flavoring
Agent etc., are thoroughly mixed and make particle, by the wet granular made 60～70 DEG C of drying 2～4h tabletted,
Obtain compound medicine tablet.
This prevention and to treat haemophiliachemophiliac compound medicine be capsule；Its preparation method is, by above-mentioned weight
Part proportioning weighs each component, adds filler, adhesive, disintegrant, the lubricant of 35%～50%, rectifys
Taste agent etc., are thoroughly mixed and make particle, by the wet granular made at 60～70 DEG C of drying 2～4h, then
It is filled in hungry area shell, obtain compound medicine capsule.
This prevention and treat haemophiliachemophiliac compound medicine for for freeze drying powder injection；Its preparation method is, by above-mentioned
Weight weigh each component, add solvent, the preservative of 60%～80%, be sufficiently mixed, add work
Property carbon decoloring, filter, with less than 0.45 μm of micro-air filter membrane filtration, embedding after ultrafiltration, 100 DEG C of sterilizings 30～60
H, makes every mL 500mg containing composition；Or after gained filtrate is dispensed by standard, freezing under vacuum
It is dried, obtain compound medicine freeze drying powder injection.
This prevention and to treat haemophiliachemophiliac compound medicine be granule；Its preparation method is, by above-mentioned weight
Part proportioning weighs each component, add 45%～75% filler, disintegrant, flavouring etc., be sufficiently stirred for
Mixing makes particle with 12～14 mesh sieves, at 60-70 DEG C of drying 2～4h, makes every gram of granule contain each component
Composition 800mg, obtains compound medicine granule.
Described filler includes lactose, sucrose, starch, microcrystalline cellulose, sorbierite, cellulose.Described
Adhesive includes gelatin, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, starch, dextrin.Described collapse
Solution agent: microcrystalline cellulose, sodium carboxymethyl starch, sodium carboxymethylcellulose, polyvinylpyrrolidone.Described
Lubricant: magnesium stearate；High-molecular bone frame material, such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose,
Ethyl cellulose, Brazil wax, hydrogenated vegetable oil, acrylic resin.
Pharmacology analysis:
Moutan bark: bitter, pungent, is slightly cold.The thoughts of returning home, liver, kidney channel.Function cures mainly: clearing heat and cooling blood, invigorating blood circulation
The stasis of blood.For febrile virulent maculae, hematemesis and epistaxis, night fever abating at dawn, lossless hectic fever due to yin, through closing dysmenorrhoea, carbuncle sore tumefacting virus,
Fall and flutter the pain of injury.
Glutinous rehmannia: sweet, cold.The thoughts of returning home, liver, kidney channel.Function cures mainly: clearing heat and cooling blood, and yin-nourishing is promoted the production of body fluid.With
In the deep red polydipsia of pyreticosis tongue, yin asthenia generating intrinsic heat, hectic fever due to yin labor heat, interior heat is quenched one's thirst, and spits blood, and bleeding from five sense organs or subcutaneous tissue sends out spot dermexanthesis.
The radix paeoniae rubrathe: bitter, is slightly cold.Return Liver Channel.Function cures mainly: clearing heat and cooling blood, blood stasis removing analgesic.Send out for temperature poison
Spot, hematemesis and epistaxis, red eye, swell pain, liver-depressed hypochondrium pain, through closing dysmenorrhoea, abdominal mass is suffered from abdominal pain, injury from falling down, and carbuncle swells
Sore.
The seed of Chinese dodder: pungent, sweet, slightly warm in nature；Return liver,kidney,spleen warp；Gas and property are delayed, and can float and can sink, have
Filling liver kidney, benefit marrow, nourish the liver to improve visual acuity, the solid tire of invigorating the spleen.
Savatier monochasma herb: bitter, cool.For coughing, spit blood, dysentery characterized by blood in the stool, under band, gingivitis, mastitis, furuncle,
Take its cooling blood and hemostasis, clearing heat and detoxicating effect.
Cornu bubali: bitter salty, cold.Heat-clearing, cool blood, removing toxic substances, for pyreticosis headache, high fever coma, macula,
Tell nosebleed, child convulsion and larynx numbness and swallow the diseases such as swollen.
Cacumen biotae: bitter, is slightly cold.Return liver, gallbladder channel.Function cures mainly: and in inducing sweat, soothing the liver, rise sun.With
In cold, fever, fevers and chills alternate, distending pain in the chest and hypochondrium, irregular menstruation, sub-official prolapses, prolapse of the anus.
Poria cocos: sweet, light is flat.Thoughts of returning home warp, lung channel, the spleen channel, kidney channel.Difficult urination；Oedema turgor；
Phlegm and retained fluid is coughed inverse；Vomiting；Insufficiency of the spleen food is few；Have loose bowels；Palpitation and restlessness；Insomnia forgetfulness；Seminal emission gonorrhoea.
Eclipta: sweet, sour, cold.Return kidney, Liver Channel.Function cures mainly: nourishing liver and kidney, cooling blood and hemostasis.With
In tooth mobility, poliosis, dizziness tinnitus, soreness and weakness of waist and knees, YinXuXueRe, haematemesis, bleeding from five sense organs or subcutaneous tissue, hematuria,
Bloody flux, metrostaxis, traumatism and bleeding.
The fruit of glossy privet: sweet, bitter, cool in nature.Gui Jing: liver, kidney channel.For the deficiency of liver-yin and kidney-yin, soreness of waist tinnitus, palpus
Send out early white；Unseeing, poor vision；Fever due to yin deficiency, stomach trouble and gout and and hyperuricemia
The Radix Astragali: sweet, temperature.Return lung, the spleen channel.Function cures mainly: invigorating qi for strengthening superficies, diuresis torr poison, and apocenosis is held back
Sore myogenic.
Radix Codonopsis: sweet is flat.Return spleen, lung channel.Function cures mainly: tonifying middle-Jiao and Qi, strengthening spleen and tonifying lung.For spleen lung
Weakness, palpitaition of breathing hard, anorexia and loose stool, void breathes with cough and coughs, and interior heat is quenched one's thirst.
RADIX POLYGONI MULTIFLORI PREPARATA: bitter, sweet, puckery is warm in nature flat.Return liver, the heart, kidney channel.Filling liver kidney, benefiting essence-blood, crow palpus
Send out, strengthening the bones and muscles, change turbid lipopenicillinase.Sallow for the deficiency of blood, dizziness ear toot, poliosis, soreness and weakness of waist and knees, limb
Body is numb, under uterine bleeding band, and hyperlipidemia.
Asian puccoon: sweet, salty, cold.The thoughts of returning home, Liver Channel.Function cures mainly: cool blood, invigorates blood circulation, promoting eruption of detoxifying.With
Containing in blood-head poison, macula purple is black, measles without adequate eruption, sore, eczema, scald.
Radix Angelicae Sinensis: sweet, acrid, warm.Enter the heart, liver, the spleen channel.Function cures mainly: benefiting blood and regulating blood circulation, menstruction regulating and pain relieving, profit
Dry laxation.Controlling irregular menstruation, through closing stomachache, abdominal mass knot is poly-, uterine bleeding；Headache due to deficiency of blood, dizziness, impotence numbness,
Intestines are dry just difficult, weight after dysentery characterized by blood in the stool, and ulcer sore is stolen, injury from falling down.
The root of bidentate achyranthes: hardship sweet, micro-is flat.Return liver, kidney channel.Stimulate the menstrual flow by the stasis of blood, easing joint movement, inducing diuresis for treating strangurtia.With
In through closing abdominal mass, placenta retension, joint pain, foot impotence muscle contraction, hematuria blood drenches, injury from falling down.
Arillus longan: sweet, temperature.Enter the heart, the spleen channel.Function cures mainly: heart-spleen boosting, fills blood, and calms the nerves.Control void
Labor is thin and weak, insomnia, forgetful, palpitation with fear, palpitation.
The banksia rose: pungent, bitter, temperature.Return spleen, stomach, large intestine, three burnt, gallbladder channels.Function cures mainly: promoting qi circulation and relieving pain,
Reinforcing spleen to promote digestion.
Polygala root: bitter, pungent, warm.The thoughts of returning home, kidney, lung channel.Function cures mainly: intelligence development of calming the nerves, and eliminates the phlegm, detumescence.
The insomnia and dreamful sleep causing for breakdown of the normal physiological coordination between the heart and the kidney, forgetful palpitation with fear, wandering, expectoration is not well, sore swollen toxin,
Mastosis.
Hairyvein agrimony: bitter, puckery, tepor, flat.The thoughts of returning home, Liver Channel.Astringing to arrest bleeding, only dysentery, desinsection.Extensively
For the card of various bleedings, as haematemesis, hematuria, have blood in stool, uterine bleeding, spitting of blood, bleeding from five sense organs or subcutaneous tissue, dysentery, labor
The de-power of wound, the cards such as carbuncle swells, and falls and beats, traumatic bleeding.
Pseudo-ginseng: hardship sweet, micro-, temperature.Return liver, stomach warp.Function cures mainly: dissipate stasis of blood hemostasis, detumescence ding-tong.With
In spitting of blood, spit blood, bleeding from five sense organs or subcutaneous tissue, have blood in stool, uterine bleeding, traumatism and bleeding, chest and abdomen shouting pain, tumbling and swelling.
A kind of prevention of the present invention and treat that haemophiliachemophiliac compound medicine is cheap, determined curative effect, passes through drug effect
Composition is complementary to one another with reasonable compatibility, effect of each component assisting a ruler in governing a country composition and coordinates, and has short treating period, sees
Advantages such as effect is fast, good effect, and be pure natural crude drug compatibility, will not have side effects, dependence and anti-medicine
Property, it is widely used in haemophiliachemophiliac prevention, control and treatment.
Detailed description of the invention
Embodiment 1: press moutan bark the 33rd, glutinous rehmannia the 23rd, the radix paeoniae rubrathe the 18th, the seed of Chinese dodder the 17th, savatier monochasma herb the 10th, cornu bubali
10th, cacumen biotae the 14th, Poria cocos the 10th, eclipta the 23rd, the fruit of glossy privet the 9th, the Radix Astragali the 15th, Radix Codonopsis the 13rd, RADIX POLYGONI MULTIFLORI PREPARATA is the 8th, purple
The weight of grass the 11st, Radix Angelicae Sinensis the 20th, the root of bidentate achyranthes the 4th, arillus longan the 15th, the banksia rose the 9th, polygala root the 18th, hairyvein agrimony the 8th, pseudo-ginseng 15
Part proportioning weighs each component, adds the lactose of 35%～50%, gelatin, microcrystalline cellulose, lubricant, hard
Fatty acid magnesium, is thoroughly mixed and makes particle, is pressed into the wet granular made at 60～70 DEG C of drying 2～4h
Piece, obtains compound medicine tablet.
Embodiment 2: press moutan bark the 27th, glutinous rehmannia the 35th, the radix paeoniae rubrathe the 13rd, the seed of Chinese dodder the 17th, savatier monochasma herb the 5th, cornu bubali the 20th,
Cacumen biotae the 7th, Poria cocos the 15th, eclipta the 18th, the fruit of glossy privet the 12nd, the Radix Astragali the 6th, Radix Codonopsis the 17th, RADIX POLYGONI MULTIFLORI PREPARATA the 3rd, Asian puccoon is the 13rd,
The weight portion of Radix Angelicae Sinensis the 16th, the root of bidentate achyranthes the 9th, arillus longan the 11st, the banksia rose the 12nd, polygala root the 15th, hairyvein agrimony the 13rd, pseudo-ginseng 10 is joined
Ratio weighs each component, add 35%～50% starch, hydroxypropyl methyl cellulose, sodium carboxymethyl starch,
Propyl methocel, is thoroughly mixed and makes particle, by the wet granular made 60～70 DEG C of dryings 2～4
H, is then filled in hungry area shell, obtains compound medicine capsule.
Embodiment 3: press moutan bark the 30th, glutinous rehmannia the 28th, the radix paeoniae rubrathe the 15th, the seed of Chinese dodder the 15th, savatier monochasma herb the 8th, cornu bubali the 16th,
Cacumen biotae the 10th, Poria cocos the 13rd, eclipta the 20th, the fruit of glossy privet the 10th, the Radix Astragali the 12nd, Radix Codonopsis the 16th, RADIX POLYGONI MULTIFLORI PREPARATA the 6th, Asian puccoon
11st, the weight portion of Radix Angelicae Sinensis the 18th, the root of bidentate achyranthes the 7th, arillus longan the 13rd, the banksia rose the 11st, polygala root the 17th, hairyvein agrimony the 9th, pseudo-ginseng 12
Proportioning weighs each component, adds water-ethanol mixed solvent, the sorbierite of 60%～80%, is sufficiently mixed, adds
Activated carbon decolorizing, filters, with less than 0.45 μm of micro-air filter membrane filtration, embedding after ultrafiltration, 100 DEG C of sterilizings
30～60h, makes every mL 500mg containing composition；Or after gained filtrate is dispensed by standard, at vacuum condition
Lower freeze-drying, obtains compound medicine freeze drying powder injection.
Embodiment 4: press moutan bark the 31st, glutinous rehmannia the 27th, the radix paeoniae rubrathe the 16th, the seed of Chinese dodder the 14th, savatier monochasma herb the 9th, buffalo
The 15th, angle the 15th, cacumen biotae the 11st, Poria cocos the 12nd, eclipta the 21st, the fruit of glossy privet the 9th, the Radix Astragali the 13rd, Radix Codonopsis makes head
Crow the 7th, Asian puccoon the 10th, Radix Angelicae Sinensis the 19th, the root of bidentate achyranthes the 6th, arillus longan the 14th, the banksia rose the 10th, polygala root the 18th, hairyvein agrimony is the 8th,
The weight of pseudo-ginseng 13 weighs each component, the microcrystalline cellulose of addition 45%～75%, dextrin, poly-second
Alkene pyrrolidone, is thoroughly mixed and makes particle with 12～14 mesh sieves, at 60-70 DEG C of drying 2～4h,
Make every gram of granule contain each components composition 800mg, obtain compound medicine granule.
Clinical case: (this treatment haemophiliachemophiliac compound medicine granule)
Through clinical 100 case patients checkings, take two courses for the treatment of of this treatment haemophiliachemophiliac compound medicine granule
After, the patient of 90% needs not rely on defeated clotting factor, takes medicine after four courses for the treatment of, and the patient of 92% no longer goes out
First skin, gum and arthrorrhagia phenomenon.It is down some cases:
Case 1: weigh certain, man, 1 years old half, Liaocheng of Shandong Province.After being born 3 months, skin occurs repeatedly
It livid purple piece, is diagnosed as hemophilia through local hospital inspection.Fall on steps before 2 months, whole hip swelling
Purplish red, uneasiness of crying and screaming all day, to go to see a doctor, result for the treatment of is inconspicuous.After take this compound medicine particle
After one course for the treatment of of agent, swelling and aubergine hemostasis substantially disappear, after three courses for the treatment of of taking medicine, and swelling and aubergine
Hemostasis is wholly absent, and clotting factor substantially rises after testing.
Case 2: when, man, 16 years old, Qingdao of Shandong province.Suffering from hemophilia since the childhood, general joint is repeatedly
Swell and ache, deformity 5 years, lie in bed 2 years, skin sheet extravasated blood, double knees, duplex joint are abnormal.Over 5 years, instead
Multiple hematuria more than 20 times, the hundreds thousand of unit of sequential treatment cost, the outbreak of result hematuria is more and more frequent, uses blood
Goods are more and more many.After taking two courses for the treatment of of this compound medicine granule, gross hematuria disappears, skin extravasated blood
Phenomenon is clearly better, and painful swelling of joints substantially mitigates, and after four courses for the treatment of of taking medicine, routine urinalysis is normal, skin extravasated blood
Phenomenon disappears substantially, and painful swelling of joints phenomenon disappears substantially, after six courses for the treatment of of taking medicine, and can out-of-bed activity.1 year
After follow up a case by regular visits to, the state of an illness is basicly stable, without bleeding, can freely activity.
Case 3: business, man, 4 years old, Zibo City of Shandong Province.Patient is upon being born, and skin occurs as soon as greatly
Piece ecchymosis, subsequently skin, arthrorrhagia repeatedly, clotting factor constantly declines.Once whole nation various big hospital was removed
Seek medical advice interrogation, all at a loss what to do.After taking one course for the treatment of of this compound medicine granule, painful swelling of joints disappears,
Taking medicine after three courses for the treatment of, clotting factor reaches normal level on inspection, follows up a case by regular visits to, stable disease, nothing after 1 year
Bleeding.
Case 4: Wu, man, 2 years old, Jinan City, Shandong Province.After being born 8 months, collision rift skin is anti-
Appear again now livid purple, patch, nosebleed, mucous membrane of mouth haemophilia, check that in provincial hospital part blood coagulation is lived
The enzyme time (KPTT) extends (68.5 seconds), can be corrected by normal serum, but can not be adsorbed blood plasma and correct,
Prompting hemophilia B, applies PCC to stop blooding repeatedly, and the large stretch of ecchymosis in skin many places, nose goes out
Blood, VIII factor active the 40%th, IX factor active the 1.2%th, XI factor active 102%, it is diagnosed as blood friend
Sick FIX deficiency disease, skin soft tissue and nosebleed.Take this compound medicine granule, blood friend's mixture, stop
The non-blood goods therapies of combing traditional Chinese and Western medicine such as blood mixture.Nosebleed stopped the same day, and after one week, skin ecchymosis disappears,
After treatment discharge in two weeks, follows up a case by regular visits to four months nothings repeatedly, and physique is clearly better.Make self blood coagulation of patient because of
Sub-activity is improved, thus reduces the incidence of disease of patient, or does not falls ill, and tackles the problem at its root.
Case 5: grandson, man, 8 years old；Jinan City, Shandong Province.Double ankle-joints swell and ache 2 years unbearably repeatedly,
Impact study.One disease does not heals, and presents blood urine again, and family circle is very worried, asks that doctor seeks medicine everywhere.Shandong hospital
Having a medical check-up: double ankle swelling, tenderness is positive.Gross hematuria.FVIII:C2.2%, ultrasound diagnosis: left
Pyelolithiasis.Diagnosis: hemophilia A, double ankle arthritis, left renal pelvis calculus hematuria.Take this compound medicine
The non-blood goods therapies of combing traditional Chinese and Western medicine such as granule, benefit peaceful, the Clofenamic Acid joint cavity injection of blood three days, joint
Swelling and ache disappearance, hematuria stops, discharge in three weeks, and it is steady to follow up a case by regular visits to four months state of an illness, and nothing is repeatedly.
Above-mentioned embodiment is intended to illustrate the present invention and can realize for professional and technical personnel in the field or use,
Above-mentioned embodiment is modified and will be apparent from for those skilled in the art, therefore this
Invention includes but is not limited to above-mentioned embodiment, and any the claims or specification of meeting describes, and meets
With principles disclosed herein and novelty, the method for inventive features, technique, product, each fall within this
Within bright protection domain.
Claims (7)
1. prevent and treat a haemophiliachemophiliac compound medicine, it is characterized in that: by following components according to shown weight ratio scope
Be prepared from, moutan bark 27-33, glutinous rehmannia 23-35, radix paeoniae rubrathe 13-18, seed of Chinese dodder 12-17, savatier monochasma herb 5-10, cornu bubali 10-20,
Cacumen biotae 7-14, Poria cocos 10-15, eclipta 18-23, fruit of glossy privet 9-12, Radix Astragali 6-15, Radix Codonopsis 13-17, RADIX POLYGONI MULTIFLORI PREPARATA 3-8,
Asian puccoon 11-13, Radix Angelicae Sinensis 16-20, root of bidentate achyranthes 4-9, arillus longan 11-15, banksia rose 9-12, polygala root 15-18, hairyvein agrimony 8-13,
Pseudo-ginseng 10-15.
2. according to claim 1 prevent and treat haemophiliachemophiliac compound medicine, it is characterized in that: described compound medicine by with
Lower component is prepared from according to shown weight ratio scope, moutan bark the 30th, glutinous rehmannia the 28th, the radix paeoniae rubrathe the 15th, the seed of Chinese dodder the 15th, savatier monochasma herb
8th, cornu bubali the 16th, cacumen biotae the 10th, Poria cocos the 13rd, eclipta the 20th, the fruit of glossy privet the 10th, the Radix Astragali the 12nd, Radix Codonopsis the 16th, RADIX POLYGONI MULTIFLORI PREPARATA is the 6th, purple
Grass the 11st, Radix Angelicae Sinensis the 18th, the root of bidentate achyranthes the 7th, arillus longan the 13rd, the banksia rose the 11st, polygala root the 17th, hairyvein agrimony the 9th, pseudo-ginseng 12.
3. according to claim 1 and 2 prevent and treat haemophiliachemophiliac compound medicine, it is characterized in that: this compound medicine agent
Type is tablet, capsule, powder-injection or granule.
4. according to claim 3 prevent and treat haemophiliachemophiliac compound medicine, it is characterized in that: this compound medicine is tablet；
Its preparation method is, weighs each component by the weight as described in claim 1 to 2 is arbitrary, adds the filling of 35%-50%
Agent, adhesive, disintegrant, lubricant, flavouring, be thoroughly mixed and make particle, by the wet granular made at 60-70 DEG C
It is dried 2-4h tabletted, obtain compound medicine tablet.
5. according to claim 3 prevent and treat haemophiliachemophiliac compound medicine, it is characterized in that: this compound medicine is capsule
Agent；Its preparation method is, weighs each component by the weight as described in claim 1 to 2 is arbitrary, adds 35%-50%'s
Filler, adhesive, disintegrant, lubricant, flavouring, be thoroughly mixed and make particle, by the wet granular made at 60-70 DEG C
It is dried 2-4h, be then filled in hungry area shell, obtain compound medicine capsule.
6. according to claim 3 prevent and treat haemophiliachemophiliac compound medicine, it is characterized in that: this compound medicine is powder pin
Agent；Its preparation method is, weighs each component by the weight as described in claim 1 to 2 is arbitrary, adds 60%-80%'s
Solvent, preservative, be sufficiently mixed, and adds activated carbon decolorizing, filters, with less than 0.45 μm of filtering with microporous membrane, after ultrafiltration
After gained filtrate is dispensed by standard, freeze-drying under vacuum, obtain compound medicine powder-injection.
7. according to claim 3 prevent and treat haemophiliachemophiliac compound medicine, it is characterized in that: this compound medicine is particle
Agent；Its preparation method is, weighs each component by the weight as described in claim 1 to 2 is arbitrary, adds 45%-75%'s
Filler, disintegrant, flavouring, be thoroughly mixed and make particle with 12-14 mesh sieve, at 60-70 DEG C of dry 2-4h, makes
Every gram of granule contains each components composition 800mg, obtains compound medicine granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410049630.8A CN103784589B (en) | 2014-02-13 | 2014-02-13 | One is prevented and treats haemophiliachemophiliac compound medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410049630.8A CN103784589B (en) | 2014-02-13 | 2014-02-13 | One is prevented and treats haemophiliachemophiliac compound medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103784589A CN103784589A (en) | 2014-05-14 |
| CN103784589B true CN103784589B (en) | 2016-10-05 |
Family
ID=50660926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410049630.8A Expired - Fee Related CN103784589B (en) | 2014-02-13 | 2014-02-13 | One is prevented and treats haemophiliachemophiliac compound medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103784589B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104258057A (en) * | 2014-09-22 | 2015-01-07 | 商秋伟 | Traditional Chinese medicine preparation for treating hemophilia |
| CN105381302A (en) * | 2015-12-16 | 2016-03-09 | 马凯 | Drug for treating hemophilia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3471076B2 (en) * | 1994-05-21 | 2003-11-25 | 株式会社資生堂 | Hypnotic perfume composition |
| CN1058616C (en) * | 1995-01-18 | 2000-11-22 | 郭崐 | Compound medicine for curing hemophilia and producing technology thereof |
| JPH0923849A (en) * | 1995-07-14 | 1997-01-28 | Moritani Kenko Shokuhin Kk | Health food for quiet sleep |
| CN1228078C (en) * | 2003-07-24 | 2005-11-23 | 姜宏英 | Medicine composition for treating hematopiesis and its use |
| CN102058714A (en) * | 2009-11-17 | 2011-05-18 | 天津天成制药有限公司 | Medicinal composition for treating hemophilia |
| CN102091292B (en) * | 2010-12-06 | 2012-05-30 | 田曼霖 | Traditional Chinese medicine composition for treating hemophilia |
-
2014
- 2014-02-13 CN CN201410049630.8A patent/CN103784589B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103784589A (en) | 2014-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107A (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN106490606A (en) | A kind of heat clearing away Mel and preparation method thereof | |
| CN103784589B (en) | One is prevented and treats haemophiliachemophiliac compound medicine | |
| CN102961589B (en) | Traditional Chinese medicine composition for treating amnesia | |
| CN106138785A (en) | One treats neurasthenic Chinese medicine composition and preparation method thereof | |
| CN103316217B (en) | Traditional Chinese medicine preparation for treating heart diseases and preparation method therefor | |
| CN106036880A (en) | Composition for relieving dysmenorrhea, application thereof and healthy food prepared from composition | |
| CN111388625A (en) | Traditional Chinese medicine composition for regulating and treating blood stasis constitution and preparation and application thereof | |
| CN104524253B (en) | A kind of Chinese medicine composition for treating pregnancy period and women breast-feeding their children's toothache | |
| CN103961578A (en) | Traditional Chinese medicine medicinal liquor for treating neurasthenia | |
| CN107898990A (en) | A kind of Chinese medicine preparation for treating neurosis and preparation method thereof | |
| CN103446462A (en) | Traditional Chinese medicine for treating oral ulcer | |
| CN109464628A (en) | A kind of Chinese medicine composition for treating insomnia | |
| CN102641442B (en) | Traditional Chinese medicine preparation for treating recurrent aphthae | |
| CN107375686A (en) | A kind of Chinese medicine composition and preparation method that can effectively treat vital myocarditis | |
| CN105214001B (en) | A kind of Chinese medicine composition for treating hypertensive patients coronary heart disease | |
| CN104491537A (en) | Traditional Chinese medicine composition for treating rheumatic heart disease | |
| CN105560561A (en) | Traditional Chinese medicine for treating aconuresis | |
| CN105031499A (en) | Traditional Chinese medicine composition for treating duodenal ulcer | |
| CN104771616A (en) | Traditional Chinese medicine preparation for treating neurasthenia and preparation method thereof | |
| CN104771560B (en) | A kind of medicine for the treatment of mania | |
| CN104398594A (en) | Pharmaceutical composition for treating children's inguinal hernia and preparation method thereof | |
| CN103007170A (en) | Chinese medicinal composition for treating recurrent oral ulcer | |
| CN107095953A (en) | A kind of Chinese medicine for treating pregnant depression | |
| CN108096493A (en) | A kind of traditional Chinese herbal decoction and its processing method for treating menalgia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wei Jianhua Inventor before: Xu Yanyan |
|
| CB03 | Change of inventor or designer information | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170801 Address after: 300000 Tianjin Binhai New Area Dagang East Fu Jinyuan No. 6 Building 3 unit 602 Patentee after: Wei Jianhua Address before: 266000 Shandong Province, Qingdao city Nanjing road 138 No. 403 Patentee before: Xu Yanyan |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180223 Address after: 232100 Han Zhuang team 025-3 in Kui village, Guangliu village, Guangxi village, Fengtai County, Anhui Province Patentee after: Han Wei Address before: 300000 Tianjin Binhai New Area Dagang East Fu Jinyuan No. 6 Building 3 unit 602 Patentee before: Wei Jianhua |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161005 Termination date: 20180213 |